4.7 Review

Diagnosis and management of gastrointestinal complications in adult cancer patients: evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)

Journal

ANNALS OF ONCOLOGY
Volume 24, Issue 5, Pages 1189-1202

Publisher

ELSEVIER
DOI: 10.1093/annonc/mdt001

Keywords

diarrhea; enterocolitis; fever; gastrointestinal; neutropenia

Categories

Funding

  1. German Federal Ministry of Research and Education (BMBF) [01KN0706]
  2. Astellas Pharma
  3. Bayer
  4. Basilea
  5. Genzyme
  6. Gilead Sciences
  7. Pfizer
  8. Merck
  9. Optimer
  10. Schering-Plough
  11. Vicuron
  12. 3M
  13. Essex/Schering-Plough
  14. Gilead
  15. Janssen-Cilag
  16. Merck/MSD
  17. Novartis
  18. Roche
  19. Shire
  20. MSD

Ask authors/readers for more resources

Background: Cancer patients frequently suffer from gastrointestinal complications. However, a comprehensive, practical and evidence-based guideline on this issue is not yet available. Patients and methods: An expert group was put together by the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO) to develop a guideline on gastrointestinal complications in cancer patients. For each subtopic, a literature search was carried out in PubMed, Medline and Cochrane databases and the strength of recommendation and the quality of the published evidence for major therapeutic strategies were categorized using a modification of the 'Infectious Diseases Society of America' criteria. Consensus discussions were held on each of the topics. Results: Recommendations were made with respect to non-infectious and infectious gastrointestinal complications. For all recommendations, the strength of the recommendation and the level of evidence are presented. Conclusion: This guideline is an evidence-based approach to the diagnosis and management of gastrointestinal complications in cancer patients.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available